ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT).

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

“…ERCC1 expression stratified by human papillomavirus (HPV) status in head and neck cancers. At the end, 17 studies containing 1288 patients were included in metaanalysis [11][12][13][14][15][22][23][24][25][26][27][28][29][30][31][32][33].…”

“…Studies were published between 2007 and 2014 and sample sizes of datasets ranged from 26 to 176. Nine studies were conducted in Caucasian patients [13-15, 23-25, 27-28, 30], seven studies in Asian patients [22,26,[28][29][32][33] and one in South American patients [11].…”

“…In 4 studies ERCC1 expression was determined by more than one method of detection in the same population of patients [11,[14][15]23]. Three studies employed RT-PCR along with IHC [11,15,23].…”

“…Three studies employed RT-PCR along with IHC [11,15,23]. Among IHC employing studies distinction was made between the most frequently used 8F1 antibody and other IHC methods.…”

“…Besides ERCC1 plays a role in several other DNA repair pathways like homologous recombination [8], interstrand cross-link repair [9] and repair of DNA double-strand breaks (DSB) [10]. A correlation between level of ERCC1 expression and clinical outcomes of HNSCC patients treated with platinum-containing therapy has been investigated in numerous studies but the results were not consistent [11][12][13][14][15].…”